| Gilead Sciences |
|Founder||Michael L. Riordan|
|Headquarters||Foster City, California|
|Interest of||McLarty Associates|
|Membership||• Daniel O’Day|
• Andrew Dickinson
• William Lee
• Jyoti Mehra
• Johanna Mercia
• Merdad Parsey
• Brett A. Pletcher
• Christi Shaw
• Taiyin Yang
• Donald Rumsfeld
• George P. Shultz
• Étienne Davignon
|a pharma company with deep state connections|
Gilead Sciences, Inc. is an American biopharmaceutical company that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including the heavily promoted Tamiflu and Remdesivir.
COVID-19 and $2000 Remdesivir
During the 2020 Covid-19 pandemic, Anthony Fauci publicly talked up Gilead's remdesivir, a drug used on people hospitalised with severe Covid-19, a procedure similar to the 2009 pushing of Tamiflu as a wonder medicine (governments in the end had to destroy big stockpiles of expensive surplus stock of an ineffective medicine).
During the Covid-19 pandemic, Gilead announced the price for a treatment with remdesivir in Europe would be 2,000 Euro ($ 2,340) per corona patient. In the US the price for private health insurance is about a third higher. 
According to Gilead-CEO Daniel O’Day, this is a bargain. In an open letter, he stated: "In normal circumstances, we would price a medicine according to the value it provides." Studies showed "that remdesivir shortened time to recovery by an average of four days. Taking the example of the United States, earlier hospital discharge would result in hospital savings of approximately $12,000 per patient."
The trial of Remdesivir was manipulated by Gilead: “Death and other negative outcomes were moved to secondary measure status: They would still be tracked, but they would no longer be the key measure of remdesivir’s performance. The switch — which specialists said is unusual in major clinical trials but not unheard of — was publicly disclosed on the government’s clinicaltrials.gov website on April 16 but did not receive much attention at the time.”
In June 1987, Gilead Sciences was originally founded under the name Oligogen by Michael L. Riordan, a medical doctor. Three scientific advisers worked with Riordan to create the company: Peter Dervan of Caltech, Doug Melton of Harvard, and Harold M. Weintraub of the Fred Hutchinson Cancer Research Center. Riordan served as CEO from the company's founding until 1996.
The company's primary therapeutic focus was in antiviral medicines. Since their founding in 1987, Gilead has routinely sought out partners for their drug products rather than trying to market them alone. Simultaneously they have attempted to grow by frequently acquiring their competitors.
In 1999, Roche announced FDA approval of Tamiflu (oseltamivir) for the treatment of influenza. Tamiflu was originally discovered by Gilead and licensed to Roche for late-phase development and marketing.
In 2002 Gilead changed its corporate strategy to focus exclusively on antivirals.
Federal disclosure forms indicate that Rumsfeld as Secretary of Defense owned between USD$5 million and USD$25 million in Gilead stock. The rise in Gilead's share prices from USD$35 to USD$57 per share added between USD$2.5 million to USD$15.5 million to Rumsfeld's net worth, especially from government purchases of Tamiflu. In November 2005, George W. Bush urged Congress to pass $7.1 billion in emergency funding to prepare for the possible H5N1(bird flu) pandemic, of which one billion is solely dedicated to the purchase, and distribution of Tamiflu.
Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500.